Phase 1 N=33 A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma
Malignant Melanoma
Primary: Number of Participants (%) With CTCAE Graded Adverse Events — 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=4,076 Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
Herpes Labialis
Primary: Lesion Healing — 107.47; 110.08; 112.41 hours
Phase 2 N=345 Non-invasive Treatment of Root Caries in Older Adults
Root Caries
Primary: Root Caries Activity — 3.72; 40.52 Percentage of active lesions (2-years)
Phase 2 N=71 Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
Neovascularization, Choroidal · Macular Degeneration, Age-Related
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 40, Using the Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA Charts — 9.3; 12.5; 11.4…
Phase 2 N=21 A Study of Intravenous Perampanel in Japanese Participants With Epilepsy
Epilepsy · Seizures
Primary: Number of Participants With Serious Adverse Events (SAEs) — 0; 1; 2 Participants
N/A N=7 Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
Neovascular Glaucoma
Primary: Incidence of Adverse Events — 3; 4 Participants
Phase 2 N=30 Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
Skin Basal Cell Carcinoma
Primary: Overall Response Rate — 69.7 percentage of tumor lesions
Phase 2 N=20 Mirabegron For Erectile Dysfunction
Erectile Dysfunction · Overactive Bladder · Urinary Incontinence
Primary: Erectile Function Assessed by IIEF Questionnaire — 12.7 score on a scale
N/A N=150 Patient-controlled Sedation With Propofol Versus Combined Sedation During Bronchoscopy
Sedation, Bronchoscopy
Primary: Discharge Assessment Using PADSS After 2 Hours Number of Patients Reaching PADSS Score 10 After 2 Hours — 19; 30; 45 Participants
Phase 2 N=27 DHA Supplementation for Lactating Mothers
Docosohexaenoic Acid Supplementation of Mothers to
Primary: Infant Serum Soluble Receptor for AGE (sRAGE) Levels at 4 Weeks From Baseline From Mothers Supplemented With 200 or 1000 mg/kg Per Day of DHA — 900; 1127 pg/mL
N/A N=18 A Trauma-Informed Approach for Positive Youth Development for Montana Students
Depression, Anxiety · Adolescent Behavior · Stress
Primary: Salivary Cortisol Testing — 0.245; 0.3088 ug/dl
Phase 2 N=31 Triptorelin for Ovary Protection in Childhood Onset Lupus
Systemic Lupus Erythematosus
Primary: Dose of Triptorelin for Ovarian Suppression — NA; 120 μg/kg
Phase 2 N=452 Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy
Primary: Mean Change From Baseline to Week 5 in Average Daily Pain Score (ADPS) Following Treatment With DS-5565 Compared to Pregabalin and Placebo — -1.86; -1.79; -2.04; -2.32…
Phase 3 N=486 Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea
Rosacea
Primary: Mean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count — 65.47; 67.89; 55.51 percentage of lesion reduction
Phase 3 N=50 An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
Rosacea · Erythema
Primary: Responder — 16.7 percentage of responders